• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

    10/23/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $LNTH alert in real time by email

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to discuss its financial results and provide a business update for the third quarter of 2025.

    To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.

    A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.

    About Lantheus

    Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland, and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for nearly 70 years. For more information, visit www.lantheus.com.

    Contacts:

    Mark Kinarney

    Vice President, Investor Relations

    978-671-8842

    [email protected]

    Melissa Downs

    Executive Director, External Communications

    646-975-2533

    [email protected]



    Primary Logo

    Get the next $LNTH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LNTH

    DatePrice TargetRatingAnalyst
    10/8/2025$77.00Buy → Neutral
    Goldman
    8/12/2025$63.00Buy → Hold
    Truist
    12/18/2024$143.00Buy
    Goldman
    9/3/2024$175.00Buy
    Redburn Atlantic
    7/10/2024$100.00 → $130.00Mkt Outperform
    JMP Securities
    12/18/2023Outperform → Mkt Perform
    William Blair
    12/4/2023$100.00Outperform
    TD Cowen
    9/29/2023Outperform
    William Blair
    More analyst ratings

    $LNTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lantheus Holdings downgraded by Goldman with a new price target

    Goldman downgraded Lantheus Holdings from Buy to Neutral and set a new price target of $77.00

    10/8/25 8:24:33 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Holdings downgraded by Truist with a new price target

    Truist downgraded Lantheus Holdings from Buy to Hold and set a new price target of $63.00

    8/12/25 7:56:11 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Goldman initiated coverage on Lantheus Holdings with a new price target

    Goldman initiated coverage of Lantheus Holdings with a rating of Buy and set a new price target of $143.00

    12/18/24 7:37:47 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Treasurer Marshall Robert J. Jr. covered exercise/tax liability with 727 shares, decreasing direct ownership by 0.82% to 88,133 units (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    9/3/25 4:29:54 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Member of a Group Owning 10% Patel Rajiv A sold $191,213,690 worth of shares (3,406,000 units at $56.14) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    8/21/25 5:27:34 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Member of a Group Owning 10% Farallon Partners L L C/Ca sold $191,213,690 worth of shares (3,406,000 units at $56.14) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Issuer)

    8/21/25 5:27:04 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Investors Turn to AI-Driven Imaging Firms Targeting High-Growth Breast Cancer Market

    NetworkNewsWire Editorial Coverage NEW YORK, Oct. 23, 2025 /PRNewswire/ -- Artificial intelligence (AI) continues to transform healthcare innovation, with medical imaging emerging as one of its most promising frontiers. In breast cancer detection, where early identification often determines patient outcomes, AI-powered imaging technologies are pushing beyond the technical constraints of traditional mammography, tomosynthesis, and MRI. Globally, breast cancer remains the most frequently diagnosed cancer among women. The World Health Organization (WHO) reported that more than 2.3 million women were diagnosed, with approximately 670,000 losing their lives to the disease in 2022. In the United S

    10/23/25 8:30:00 AM ET
    $BFLY
    $LNTH
    $NVDA
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Semiconductors

    Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to discuss its financial results and provide a business update for the third quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    10/23/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus and GE HealthCare Announce Exclusive Licensing Agreement for Prostate Cancer Imaging Agent PYLARIFY® (Piflufolastat F 18) in Japan

    BEDFORD, Mass. and CHICAGO and TOKYO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc.  (NASDAQ:LNTH) and GE HealthCare (NASDAQ:GEHC) today announced an exclusive licensing agreement for GE HealthCare to develop, manufacture, and commercialize Lantheus' piflufolastat F18 (PYLARIFY® in U.S. market) in Japan for prostate cancer diagnostics and companion diagnostic use. PYLARIFY is used for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive lesions in men with prostate cancer. The agreement includes the transfer of regulatory dossiers, manufacturing competencies and technical support to enable GE HealthCare to drive clinical development

    9/24/25 1:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    $LNTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Lantheus Alpha Therapy, Llc bought $57,409,487 worth of shares (60,431,039 units at $0.95) (SEC Form 4)

    4 - Lantheus Holdings, Inc. (0001521036) (Reporting)

    3/8/24 11:24:53 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Lantheus Holdings Inc.

    SCHEDULE 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/14/25 11:17:17 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 144 filed by Lantheus Holdings Inc.

    144 - Lantheus Holdings, Inc. (0001521036) (Subject)

    8/13/25 12:48:42 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form 8-K filed by Lantheus Holdings Inc.

    8-K - Lantheus Holdings, Inc. (0001521036) (Filer)

    8/11/25 5:02:48 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 8:21:14 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Amendment: SEC Form SC 13G/A filed by Lantheus Holdings Inc.

    SC 13G/A - Lantheus Holdings, Inc. (0001521036) (Subject)

    11/14/24 3:29:28 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    SEC Form SC 13G filed by Lantheus Holdings Inc.

    SC 13G - Lantheus Holdings, Inc. (0001521036) (Subject)

    2/14/24 1:18:20 PM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Leadership Updates

    Live Leadership Updates

    View All

    Lantheus Completes Acquisition of Life Molecular Imaging and Appoints Dr. Ludger Dinkelborg as Head of R&D

    BEDFORD, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ:LNTH), today announced the successful completion of its previously disclosed acquisition of Life Molecular Imaging Ltd. ("Life Molecular"), a subsidiary of Life Healthcare Group Holdings Ltd ("Life Healthcare"). As part of the acquisition, Ludger Dinkelborg, PhD, formerly CEO and Managing Director of Life Molecular Imaging, has been appointed Head of Research and Development at Lantheus effective August 1, 2025. "We are thrilled to welcome Dr. Dinkelborg and the entire Life Molecular team to Lantheus," said Brian Markison, CEO of Lantheus. "Ludger's proven leadership, scientific

    7/22/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    PharmaLogic Announces Appointment of Etienne Montagut as President and Chief Executive Officer

    BOCA RATON, Fla., June 2, 2025 /PRNewswire/ -- PharmaLogic Holdings Corp. ("PharmaLogic" or "the Company"), a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals, today announces the Company has appointed Etienne Montagut, currently serving as President, to the position of President and Chief Executive Officer, effective as of 1 June 2025. Mr. Montagut brings over 25 years of senior leadership experience in the pharmaceutical sector, with a solid track record of driving growth and executing strategic transformation across glob

    6/2/25 8:00:00 AM ET
    $GEHC
    $LNTH
    Medical Electronics
    Health Care
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Lantheus Appoints Phuong Khanh (P.K.) Morrow, M.D., as New Board Member

    BEDFORD, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus") (NASDAQ:LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced the appointment of Phuong Khanh (P.K.) Morrow, M.D. to Lantheus' Board of Directors ("Board"), effective February 1, 2025. Dr. Morrow is an experienced pharmaceutical executive and physician-scientist with deep expertise leading end-to-end clinical development in the field of oncology. As an independent director, Dr. Morrow will serve as a member of the Board's Science and Technology Committee, where her proven track record i

    1/30/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $LNTH
    Financials

    Live finance-specific insights

    View All

    Lantheus to Host Third Quarter 2025 Earnings Conference Call and Webcast on November 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Thursday, November 6, 2025, to discuss its financial results and provide a business update for the third quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    10/23/25 8:30:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus Reports Second Quarter 2025 Financial Results and Provides Business Update

    Recorded second quarter 2025 worldwide revenue of $378.0 million, GAAP fully diluted earnings per share of $1.12, adjusted fully diluted earnings per share of $1.57 and free cash flow of $79.1 millionAnnounced FDA acceptance of NDA for new formulation for piflufolastat F 18 PSMA PET imaging agent with a PDUFA date of March 6, 2026Closed acquisition of Life Molecular Imaging in July, immediately expanding near- and long-term growth profile and commercial portfolio with Neuraceq® (florbetaben F 18 injection), a globally approved beta-amyloid targeted radiodiagnostic for Alzheimer's disease; FDA label expansion for Neuraceq in JuneBoard of Directors authorized a program to repurchase up to $400

    8/6/25 7:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Lantheus to Host Second Quarter 2025 Earnings Conference Call and Webcast on August 6, 2025, at 8:00 a.m. Eastern Time

    BEDFORD, Mass., July 23, 2025 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the "Company") (NASDAQ:LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday, August 6, 2025, to discuss its financial results and provide a business update for the second quarter of 2025. To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time. A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least

    7/23/25 8:00:00 AM ET
    $LNTH
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care